Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06429280 · ClinicalTrials.gov registry record
Clinical Data Registry of Amblyopia Patients on Luminopia Treatment
A clinical trial of Amblyopia, sponsored by Luminopia.
- Recruiting
- Registry status
- 500
- Enrollment target
- 13
- Study locations
NCT06429280: Recruiting study of Amblyopia, sponsored by Luminopia.
NCT06429280 is a study of Amblyopia that is actively recruiting participants, run by Luminopia. The registered enrollment target is 500 participants, above the 145-participant average among 24 other Amblyopia trials with a reported enrollment target (245% higher). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06429280, a study of Amblyopia, is actively recruiting participants, sponsored by Luminopia.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 13
- Study locations
Study Summary
Amblyopia is the most prevalent cause of reduced monocular visual acuity in children and young adults, with estimates of prevalence ranging from 1% to 5%. The most common associated amblyogenic risk factors are uncorrected anisometropia, strabismus, or a combination of these. In addition to reduced visual acuity, amblyopic patients may also have measurable dysfunction of accommodation, fixation, binocularity, vergence, reading fluency, depth perception, and contrast sensitivity. For the first time since the incorporation of atropine penalization into amblyopia management, physicians can now offer Luminopia, an FDA-approved dual action dichoptic treatment, to patients with amblyopia. Since the product became commercially available in November 2022, the number of patients on Luminopia therapy continues to grow. This presents a unique opportunity to gather real world evidence from a large number of patients, representative of how ophthalmologists and optometrists are applying this novel treatment in the real world. A registry of the clinical data associated with Luminopia treatment, with IRB oversight, will provide answers to key scientific questions using a large dataset.
Primary Outcome
Change in Visual Acuity from baseline to consecutive visits
Conditions Studied
Interventions
- DEVICE N/A this is an observational study of Standard of Care
Study Locations (13)
Florida
- Okaloosa Ophthalmology - Crestview
- Family Focus Eye Care - Gainsville
- Eye Physicians of Central Florida - Maitland
California
- UCSF Benioff Children's Physicians - San Ramon
- Sansum Clinic - Santa Barbara
Georgia
- Children's Eye Institute of Savannah - Savannah
Hawaii
- Honolulu Eye Clinic - Honolulu
Illinois
- Lurie Children's Hospital - Chicago
Indiana
- Riley Children's Hospital at IU Health - Indianapolis
Nevada
- Nevada Eye Physicians - Las Vegas
New Hampshire
- Concord Eye Center - Concord
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2026-12-31 |
What NCT06429280 shows while recruiting
NCT06429280 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 145-participant average among 24 other Amblyopia trials with a reported enrollment target (245% higher).
The record links to 1 condition, with Amblyopia appearing as the primary indexed condition, and to 1 intervention - of which N/A this is an observational study of Standard of Care is the first listed.
NCT06429280 lists 13 locations in 10 states (Florida, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT06429280 about?
NCT06429280 is a clinical study titled "Clinical Data Registry of Amblyopia Patients on Luminopia Treatment". Amblyopia is the most prevalent cause of reduced monocular visual acuity in children and young adults, with estimates of prevalence ranging from 1% to 5%. The most common associated amblyogenic risk factors are uncorrected anisometropia, strabismus, or a combination of these. In addition to reduced ...
What is the current status of trial NCT06429280?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-09-01. Estimated completion is 2026-12-31.
What conditions does trial NCT06429280 study?
This clinical trial studies the following conditions: Amblyopia.
What interventions are being tested in trial NCT06429280?
The interventions under investigation include: N/A this is an observational study of Standard of Care (DEVICE).
Who is sponsoring clinical trial NCT06429280?
This trial is sponsored by Luminopia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06429280 being conducted?
This trial has 13 study locations across California, Florida, Georgia, Hawaii, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amblyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06429280's enrollment target sits among peer trials
500 2nd of 24 the highest of 24 other Amblyopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amblyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Noninvasive Brain Stimulation in Adult Amblyopia
RECRUITING · NA
-
OCT Eccentric Fixation and Amblyopia in Children
RECRUITING · NA
-
Visual Function Abnormalities in Strabismus and Amblyopia and Response to Therapy
RECRUITING
-
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
RECRUITING · Phase 3
-
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
RECRUITING · Phase 3
-
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI